RENAGADE
Live / Registered — Registered (as of 24 Mar 2026)
What this means for you
Registered since 24 Mar 2026. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 90545043
- Registration number
- 8187837
- Mark type
- Stylized text
- Filed
- 24 Feb 2021
- Published for opposition
- 17 Jan 2023
- Registered
- 24 Mar 2026
- Attorney of record
- Jonathan M. Gelchinsky
Goods and services
- Class 005 — Pharmaceuticals: Pharmaceutical preparations and substances, namely, RNA therapeutics for the treatment of infectious diseases, blood disorders, and inflammation; pharmaceutical preparations, namely, RNA therapeutics for the prevention of cancers, inflammatory disorders, immunoregulatory disorders, infectious disorders; pharmaceutical preparations, namely, RNA therapeutics for the treatment of immune system related diseases and disorders; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the treatment of viral infections; pharmaceutical preparations, namely, RNA therapeutics for the treatment of cancers, inflammatory disorders, immunoregulatory disorders, and infectious disorders; pharmaceutical preparations, namely, RNA therapeutics for use in chemotherapy; pharmaceutical preparations, namely, RNA therapeutics for cancers, inflammatory disorders, immunoregulatory disorders, infectious disorders; pharmaceutical preparations, namely, antivirals; therapeutic pharmaceuticals, namely, RNA therapeutics for the treatment of cancers, inflammatory disorders, immunoregulatory disorders, infectious disorders; vaccine preparations, namely, RNA vaccine preparations; vaccines, namely, RNA vaccines; human vaccine preparations, namely, RNA vaccine preparations; medical preparations for the treatment of cancers, inflammatory disorders, immunoregulatory disorders, infectious disorders; medicinal preparations for the treatment of infectious diseases and for use in oncology; mixed biological preparations, namely, RNA therapeutics for the prevention and treatment of infectious diseases; pharmaceutical preparations, namely, RNA therapeutics for the prevention and treatment of autoimmune diseases or disorders; pharmaceutical preparations for the treatment of viral diseases; pharmaceutical products, namely, RNA therapeutics for the treatment of viral and infectious diseases, for the treatment of cancer; therapeutic vaccines, namely, RNA therapeutics; all of the foregoing excluding medicinal dietary and nutritional supplements
Owner
- Renagade Therapeutics LLC, Watertown, MA, US
- Renagade Therapeutics LLC, Watertown, MA, US
- Renagade Therapeutics LLC, Cambridge, MA, US
Prosecution history
- 24 Mar 2026 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 24 Mar 2026 — REGISTERED-PRINCIPAL REGISTER
- 05 Mar 2026 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 05 Mar 2026 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 05 Mar 2026 — STATEMENT OF USE PROCESSING COMPLETE
- 04 Mar 2026 — USE AMENDMENT FILED
- 04 Mar 2026 — TEAS STATEMENT OF USE RECEIVED
- 29 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 29 Dec 2025 — SOU EXTENSION 5 GRANTED
- 11 Aug 2025 — SOU EXTENSION 5 FILED
- 29 Dec 2025 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 11 Aug 2025 — SOU TEAS EXTENSION RECEIVED
- 13 Feb 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 13 Feb 2025 — SOU EXTENSION 4 GRANTED
- 12 Feb 2025 — SOU EXTENSION 4 FILED